D&D Pharmatech Reports P-II Trial Results on Zabopegdutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Why It Matters

The data suggest zabopegdutide could become a first‑in‑class therapy that simultaneously reverses liver fibrosis and resolves steatohepatitis, addressing a major unmet need in the rapidly growing MASH market.

Key Takeaways

• Zabopegdutide achieved 50% fibrosis improvement vs 15.8% placebo
• 62.5% of patients resolved MASH without fibrosis worsening
• 37.5% showed both fibrosis improvement and MASH resolution
• Trial enrolled 67 overweight/obese patients across the United States
• Weekly 40 mg dose followed 2‑week titration, high adherence observed

Pulse Analysis

Metabolic dysfunction‑associated steatohepatitis, commonly known as MASH, has emerged as a leading cause of chronic liver disease worldwide, driven by rising obesity and type‑2 diabetes rates. Unlike traditional non‑alcoholic fatty liver disease, MASH carries a high risk of progression to cirrhosis and liver‑related mortality, yet no approved pharmacologic therapy directly targets both fibrosis and inflammation. Industry analysts estimate the global MASH market could exceed $30 billion by 2030, making any breakthrough therapy a potential game‑changer for patients and investors alike.

The Phase II DD01‑DN‑02 trial offers a compelling efficacy signal. Among the per‑protocol cohort of 35 biopsy‑confirmed MASH patients, half achieved at least a one‑stage fibrosis regression without disease worsening, a stark contrast to the sub‑20% rate observed with placebo. Moreover, more than six in ten participants experienced complete resolution of steatohepatitis while preserving fibrosis status, and over a third achieved both outcomes simultaneously. These histologic improvements were accompanied by reductions in liver fat fraction, stiffness, and key fibrosis biomarkers, underscoring a multi‑modal mechanism that may differentiate zabopegdutide from other GLP‑1 analogues currently in development.

If the forthcoming Phase III program confirms these findings, D&D Pharmatech could secure a first‑to‑market position in a therapeutic area with limited competition. The data also bolster the broader hypothesis that GLP‑1‑based agents can modulate hepatic inflammation and fibrogenesis beyond glycemic control. Investors will likely watch for regulatory pathways, pricing strategies, and potential partnerships that could accelerate global rollout, especially in regions where MASH prevalence is accelerating alongside metabolic disease burdens.